

This PDF document is an updated note on the company. A comprehensive version of the report on the company, including this latest update, is available on [our website](#) and various professional platforms.

On **August 7, 2018**, Symbio Pharmaceuticals Ltd. announced earnings results for 1H FY12/18.

| Cumulative (JPYmn) | FY12/17 | | | | FY12/18 | | | | FY12/18 | |
|-----------------------|---------|--------|--------|--------|---------|--------|----|----|---------|---------|
| | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | % of FY | FY Est. |
| Sales | 870 | 1,786 | 2,417 | 3,444 | 888 | 1,928 | | | 45.9% | 4,201 |
| YoY | 350.2% | 47.5% | 71.7% | 45.4% | 2.1% | 8.0% | | | | 22.0% |
| Gross profit | 239 | 510 | 675 | 1,031 | 250 | 573 | | | | |
| YoY | 323.0% | 26.0% | 41.0% | 14.1% | 4.4% | 12.4% | | | | |
| GPM | 27.5% | 28.5% | 27.9% | 29.9% | 28.1% | 29.7% | | | | |
| SG&A expenses | 764 | 1,746 | 4,183 | 4,978 | 964 | 1,898 | | | | |
| YoY | 32.9% | 42.5% | 108.0% | 64.2% | 26.1% | 8.7% | | | | |
| SG&A ratio | 87.9% | 97.7% | 173.1% | 144.5% | 108.5% | 98.4% | | | | |
| Operating profit | -525 | -1,236 | -3,508 | -3,947 | -715 | -1,325 | | | - | -2,981 |
| YoY | - | - | - | - | - | - | | | | - |
| OPM | - | - | - | - | - | - | | | | - |
| Recurring profit | -583 | -1,268 | -3,547 | -3,977 | -749 | -1,378 | | | - | -3,044 |
| YoY | - | - | - | - | - | - | | | | - |
| RPM | - | - | - | - | - | - | | | | - |
| Net income | -583 | -1,266 | -3,546 | -3,978 | -760 | -1,389 | | | - | -3,056 |
| YoY | - | - | - | - | - | - | | | | - |
| Net margin | - | - | - | - | - | - | | | | - |

| Quarterly (JPYmn) | FY12/17 | | | | FY12/18 | | | |
|----------------------|---------|--------|--------|--------|---------|-------|----|----|
| | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 |
| Sales | 870 | 916 | 631 | 1,028 | 888 | 1,040 | | |
| YoY | 350.2% | -9.9% | 220.3% | 7.0% | 2.1% | 13.5% | | |
| Gross profit | 239 | 271 | 165 | 357 | 250 | 324 | | |
| YoY | 323.0% | -22.2% | 123.8% | -16.2% | 4.4% | 19.5% | | |
| GPM | 27.5% | 29.6% | 26.1% | 34.7% | 28.1% | 31.1% | | |
| SG&A expenses | 764 | 982 | 2,437 | 795 | 964 | 934 | | |
| YoY | 32.9% | 51.1% | 210.1% | -22.1% | 26.1% | -4.9% | | |
| SG&A ratio | 87.9% | 107.1% | 386.5% | 77.4% | 108.5% | 89.8% | | |
| Operating profit | -525 | -711 | -2,272 | -439 | -715 | -610 | | |
| YoY | - | - | - | - | - | - | | |
| OPM | - | - | - | - | - | - | | |
| Recurring profit | -583 | -685 | -2,279 | -430 | -749 | -629 | | |
| YoY | - | - | - | - | - | - | | |
| RPM | - | - | - | - | - | - | | |
| Net income | -583 | -684 | -2,280 | -432 | -760 | -629 | | |
| YoY | - | - | - | - | - | - | | |
| Net margin | - | - | - | - | - | - | | |

Source: Shared Research based on company data.

Note: Figures may differ from company materials due to differences in rounding methods.

1H FY12/18 results

1H FY12/18 sales totaled JPY1.9bn (+8.0% YoY) mainly owing to domestic sales of Treakisym®.

Due to the sales increase, gross profit came to JPY573mn (+12.4% YoY). Gross profit margin was 29.7% (+1.2pp).

SG&A expenses rose 8.7% YoY to JPY1.9bn. R&D expenses came in at JPY839mn (-0.1% YoY). There were expenses for clinical trials for intravenous and oral formulations of Treakisym® and rigosertib. SG&A expenses excluding R&D expenses were up 16.9% at JPY1.1bn.

As a result, operating loss totaled JPY1.3bn (loss of JPY1.2bn in 1H FY12/17). The company also reported a recurring loss of JPY1.4bn (loss of JPY1.3bn in 1H FY12/17) partly due to non-operating expenses of JPY54mn (mainly on forex losses). Net loss was JPY1.4bn (loss of JPY1.3bn in 1H FY12/17).

Domestic

Treakisym® (SyB L-0501/SyB L-1701 (RTD) /SyB L-1702 (RI) /SyB C-0501 (oral); anticancer agent; generic name: bendamustine hydrochloride)

The company markets the anticancer agent Treakisym® in Japan through its business partner, Eisai Co., Ltd. (TSE1: 4523) for the indications of refractory or relapsed low-grade non-Hodgkin's lymphoma (NHL) and mantle cell lymphoma (MCL), untreated low-grade NHL and MCL, and chronic lymphocytic leukemia (CLL). (The company obtained marketing approval for refractory or relapsed low-grade NHL and MCL in October 2010, for untreated low-grade NHL and MCL in December 2016, and for CLL in August 2016.)

As a result of additional indications, Treakisym® is steadily increasing its market share in the area of first-line treatment by replacing R-CHOP, the conventional standard treatment, and sales of Treakisym® based on the National Health Insurance (NHI) drug price grew significantly by 22.3% YoY. Product sales to Eisai is also progressing in line with plan.

In addition to the above three approved indications, the company has started Phase III clinical trials for the fourth indication of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and is currently enrolling patients for the trial with an aim to obtain approval. In response to strong medical needs, the company finished consultation with the Pharmaceuticals and Medical Devices Agency (PMDA) and began phase III clinical trials toward the addition of an indication in August 2017, enrolling the first patient in January 2018.

In addition to efforts for new indications, in September 2017, the company concluded an exclusive licensing agreement with Eagle Pharmaceuticals (based in New Jersey, US) to develop, market, and sell liquid formulations of Treakisym® (RTD and RI formulations) in Japan for Treakisym®'s product life cycle management. The RTD and RI products offer significant value added to patients and healthcare professionals, and extend Treakisym®'s product life cycle until 2031. The company has already consulted with PMDA on the details of the application for approval of the RTD formulation and clinical trial design for the RI formulation, and is preparing for the launch of Treakisym® liquid formulation in Japan in 2021 or later.

In July 2018, Symbio obtained approval for the partial revision to the marketing authorization. As a result, Treakisym® can now be used in combination with not only rituximab but also obinutuzumab after the latter's launch for the treatment of low-grade NHL, enabling the company to provide patients with a new treatment therapy.

SymBio will explore further expansion of the Treakisym® business by developing an oral formulation in addition to the injection currently under development or on sale to treat solid tumors and autoimmune diseases. In this context, the company commenced a phase I clinical trial for progressive solid tumors in January 2018, with the aim of examining the recommended dosage and schedule as well as tolerability and safety of the oral formulation of Treakisym®, and narrowing down the types of potential target tumors. The enrollment of the first patient was completed in May 2018. To evaluate the effect of oral administration of Treakisym® on the immune system, the company concluded a joint research agreement with Keio University in May 2018 and began a preclinical study to verify the efficacy of the oral form of Treakisym® in treating systemic lupus erythematosus (SLE), a form of autoimmune disease.

Rigosertib Sodium (SyB L-1101 [IV]/SyB C-1101 [oral]; anticancer agent; generic name: Rigosertib Sodium)

Onconova Therapeutics, Inc., the licensor, is currently conducting a global Phase III trial and Symbio Pharmaceuticals started the Japan trial in December 2015 (36 patients enrolled so far). The global Phase III trial addresses higher-risk myelodysplastic syndromes (MDS), which do not respond to the current standard treatment with hypomethylating agents, which relapse after treatment under the current standard of care, or which are intolerant to hypomethylating agents, and is under way at clinical trial sites in more than 20 countries worldwide. Patient enrollments are smoothly accumulating. Based on the results of an interim analysis performed in January 2018, Symbio decided to continue the trial, increasing the number of patient enrollment in accordance with a pre-determined statistical criteria. Based on these results, the company plans to apply for approval in Japan at the same time as in the U.S. and Europe.

Regarding the oral formulation of rigosertib, Onconova is conducting Phase I/II clinical trials for the drug used in combination with azacytidine as first-line treatment for higher-risk MDS and Phase II clinical trials for transfusion-dependent lower-risk MDS in the U.S. To verify the tolerability and safety of the oral formulation of rigosertib among Japanese patients, Symbio began Phase I clinical trials in Japan in June 2017 and is steadily enrolling patients. After completing the Phase I trials, the company plans to promptly start clinical trials for rigosertib used in combination with azacytidine, participate in international Phase III clinical trials of the drug used in combination with azacytidine as first-line treatment for higher-risk MDS. Onconova is planning, and apply for approval of the oral formulation of the drug in Japan at the same time as in the U.S. and Europe. In regards to development of rigosertib for transfusion-dependent lower-risk MDS, the company is considering participating from Japan while monitoring Onconova's development progress.

SyB P-1501, a post-operative patient-controlled analgesia

Regarding SyB P-1501 licensed by the Medicines Company (through its wholly owned subsidiary Incline Therapeutics, Inc.) in October 2015, Symbio found a fact that raised concerns about the continuity of its business, and in the interests of patient welfare, it suspended further patient enrollment in April 2017. The license agreement was terminated in November 2017, and the development of the drug was terminated in February 2018.

The Company initiated an arbitration against The Medicines Company in October 2017, under the rules of the International Chamber of Commerce, seeking damages of USD82mn (approximately JPY9.0bn) arising from The Medicines Company's repudiation of the license agreement. Arbitration proceedings against The Medicines Company are still ongoing.

New drug candidates

From a long-term perspective, Symbio continues to search for and evaluate promising drug candidates, in a bid to acquire global licensing rights for these drugs and grow into a sustainable and profitable biopharmaceutical company with growth potential and profitability. The company is considering licensing rights for several drug candidates. Further, in May 2016, the company established Symbio Pharma USA, Inc., a wholly owned US-based subsidiary, as a strategic base for overseas business development. The company looks to leverage this subsidiary to actively acquire rights over new drug development candidates globally, and engage in development and commercialization in major markets including the US, Japan, and Europe to transition to a global specialty pharmaceutical company.

Overseas

The company marketed SyB L-0501 in Korea, Taiwan, and Singapore, and sales were largely in line with plans.

Full-year company forecasts

| (JPYmn) | FY12/17 | | | FY12/18 | | |
|--------------------|---------|---------|---------|---------|---------|---------|
| | 1H Act. | 2H Act. | FY Act. | 1H Act. | 2H Est. | FY Est. |
| Sales | 1,786 | 1,658 | 3,444 | 1,928 | 2,273 | 4,201 |
| SG&A expenses | 1,746 | 3,233 | 4,978 | 1,898 | 2,452 | 4,350 |
| SG&A ratio | 97.7% | 194.9% | 144.5% | 98.4% | 107.9% | 103.5% |
| R&D expenses | 840 | 2,177 | 3,017 | 1,059 | 1,252 | 2,311 |
| SG&A excluding R&D | 906 | 1,055 | 1,961 | 839 | 1,200 | 2,039 |
| Operating profit | -1,236 | -2,711 | -3,947 | -1,325 | -1,656 | -2,981 |
| OPM | - | - | - | - | - | - |
| Recurring profit | -1,268 | -2,709 | -3,977 | -1,378 | -1,666 | -3,044 |
| RPM | - | - | - | - | - | - |
| Net income | -1,266 | -2,712 | -3,978 | -1,389 | -1,667 | -3,056 |
| Net margin | - | - | - | - | - | - |

Source: Shared Research based on company data.
 Figures may differ from company materials due to differences in rounding methods.

This note is the most recent addition to the [full report](#).

We offer corporate clients comprehensive report coverage, a service that allows them to better inform investors and other stakeholders by presenting a continuously updated third-party view of business fundamentals, independent of investment biases. Shared Research can be found on the web at <http://www.sharedresearch.jp>.

Disclaimer

This document is provided for informational purposes only. No investment opinion or advice is provided, intended, or solicited. Shared Research Inc. offers no warranty, either expressed or implied, regarding the veracity of data or interpretations of data included in this report. We shall not be held responsible for any damage caused by the use of this report.

The copyright of this report and the rights regarding the creation and exploitation of the derivative work of this and other Shared Research Reports belong to Shared Research. This report may be reproduced or modified for personal use; distribution, transfer, or other uses of this report are strictly prohibited and a violation of the copyright of this report. Our officers and employees may currently, or in the future, have a position in securities of the companies mentioned in this report, which may affect this report's objectivity.

Japanese Financial Instruments and Exchange Law (FIEL) Disclaimer

The report has been prepared by Shared Research under a contract with the company described in this report ("the company"). Opinions and views presented are ours where so stated. Such opinions and views attributed to the company are interpretations made by Shared Research. We represent that if this report is deemed to include an opinion by us that could influence investment decisions in the company, such opinion may be in exchange for consideration or promise of consideration from the company to Shared Research.

Contact Details

Shared Research Inc.

3-31-12 Sendagi Bunkyo-ku Tokyo, Japan

<https://sharedresearch.jp>

Phone: +81 (0)3 5834-8787

Email: info@sharedresearch.jp